Home
Clinical Trials
Effect of Sea Grapes-antioxid...

Effect of Sea Grapes-antioxidants Extract in Obese Men : 4 Weeks Randomized-Double Blind Controlled Trial

Last Updated: 2021-09-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-01

Study Completion Date

2021-09-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Doses of 150 mg/kg BW (30 mg/200g BW) sea grape extract in a previous pre-clinical trial, showed that it could improve blood glucose, total cholesterol and serum PGC-1 levels in rats fed a diet high in fat and cholesterol. In addition, you also have hepatoprotective activity (aka non-toxic) in diabetic mice. Previous research, is an in vivo (Pre-clinical) study that has not represented the benefits or efficacy of sea grape extract on variables tested in humans. Therefore, this clinical trial was conducted to support the effect of sea grape extract-antioxidant on blood glucose, total cholesterol, and PGC-1 levels in obese men for 4 weeks using a Randomized-Double Blind Controlled Trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Acute Effects of Grape Seed Extract on Insulin Sensitivity and Oxidative Stress and Inflammation Markers.

NCT01995643

Polyphenolic Compounds and Metabolism

COMPLETED NA

Assessment of Delphinol® Dose on Vascular Function

NCT07196059

Healthy

COMPLETED NA

Brown Seaweed Extract on Glycemic Control and Body Weight

NCT03075943

PreDiabetes Insulin Resistance

COMPLETED NA

Grape Polyphenols and Metabolic Syndrome

NCT04053569

Metabolic Syndrome, Protection Against

UNKNOWN NA

The Efficacy of Red Grape Seed Extract on Lipid Profile and Oxidized Low-Density Lipoprotein (OX-LDL)

NCT00713167

Hyperlipidemia

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study was a 4-week, randomized, double-blind, placebo-controlled clinical trial followed by a 1-week screening period. Participants who respond to the invitation and meet the entry criteria during the telephone screening interview are scheduled for the initial visit. Evaluation during the initial visit includes physical examination in the form of BMI (Body Mass Index) based on Asia-Pacific guidelines and blood parameter screening tests in the form of blood glucose, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and total cholesterol, and PGC-1α were performed on all participants within 1 week of the initial screening. A random number between 1 and 70 was generated for each subject and registered participants were scheduled for their first visit and randomly assigned to the sea grape extract group (n=35) or placebo (n=35). Sea grape extract/placebo tablets/capsules were given to participants every 1 week (1 day of consumption per oral) 15 Minutes before eating (According to the diabetes drug guidline consumtion).

During the 4-week intervention period, participants were asked to continue their usual diet and not to consume functional foods or other dietary supplements. Anthropometry (BMI), Waist Hip Ratio (WHR) , blood parameters, urine profile (Marker of toxicity), and nutrient intake of both groups were measured before and after the intervention period. During the trial phase, all participants were instructed to maintain their normal diet and physical activity. Each week participants were asked to report assessments of side effects or changes in training, lifestyle, or diet; and to evaluate tablet compliance.

Subjects/Participants The study participants were recruited during 2021 at Manado, Republic of Indonesia. A total of 150 participants agreed to participate in the study. Only individuals men who are obese (BMI ≥ 25 kg m-2 and Waist Hip Ratio (WHR) ≥ 0.90) according to Asia-Pacific guidelines and have not been diagnosed with other diseases were included in the study. To meet guidelines for evaluating the efficacy of functional food referring to the Korea Food and Drug Administration (because Indonesia does not yet exist and Koreas belong to one Asian region so used), very obese participants (BMI ≥ 30 kg m-2) were not included in the study.

In total, 70 participants met the research criteria (age 29.98 ± 3.26 year; weight, ..... ± .... kg; BMI, .... ±.... kg m-2) and were randomly divided into two groups (n = 35 each) given sea grape extract 1.68 g/70kg BB day-1) or placebo (1.68 g/70kg BB day-1). The exclusion criteria for this study are as follows: (a) significant weight variation (over 10%) in the last 3 months; (b) a history of cardiovascular disease including arrhythmia, heart failure, or myocardial infarction, diabetes mellitus (DM) and the use of pacemakers; (c) a history of conditions that may interfere with test products or inhibit their absorption such as gastrointestinal diseases (Crohn's disease) or surgeries that have been experienced (caesarean section or enterocele); (d) participation in other clinical trials in the last 2 months; (e) abnormal liver function; (f) a history of kidney disease (eg, acute or chronic renal failure and nephrtic syndrome); (g) undergo antipsychotic drug therapy within the last 2 months; (h) laboratory test results as well as medical or psychological conditions that may interfere with successful participation in research assessed by researchers; (i) a history of alcohol or substance abuse; and (j) allergy or hypersensitivity to any of the ingredients in the test product; (k) is neither a passive nor an active smoker. All participants give written consent before the investigation begins. The research protocol was submitted to the Health Research Ethics Commission (KEPK) of The General Hospital of Education Prof. Dr. RD. Kandou (Manado, Republic of Indonesia) online at http://sim-epk.keppkn.kemkes.go.id. All protocols referred to The Declaration of Helsinki and The Council for International Organizations of Medical Sciences (CIOMS).

Measurement of Efficacy Results A total of 70 participants who met the research criteria were asked to visit the clinic once every 1 week (0th, 1st, 2nd, 3rd, and 4th/last week of the study period) with a total of 5 clinical visits including initial examination. During each visit, the use of the supplement is currently reviewed and symptoms or side effects are noted. During screening visits, demographic and lifestyle information is collected (age, alcohol consumption, and smoking habits). Medical history is taken and urine turbidity tests are carried out.

The following parameters are assessed; Weight, Height, WHR and BMI during each visit. Blood samples were collected after a minimum of 12 hours of fasting during initial screening as well as in the 0, 2nd and 4th weeks of the intervention period to obtain blood glucose profiles, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and PGC-1α. Blood samples were taken from the arm vein. The arm vein to be punctured is cleaned with 70% alcohol and allowed to dry. A tourniquet is placed on the upper arm to expose and slightly accentuate the veins. The skin is stretched over the vein with the fingers of the left hand so that the vein cannot move. The skin is pierced with a needle and syringe with the right hand until the tip of the needle enters the lumen of the vein. The tourniquet is removed and slowly withdraw the syringe suction until the desired amount of blood is obtained. A 70% alcohol swab is placed over the needle and the syringe and needle are removed. The needle is removed from the syringe and the blood sample is transferred into a vacutainer tube.

Evaluation of Safety and Diet

The safety of the extract is assessed by the following procedure. Urine Test Strips 10 Verify Parameters, Parameters examined are:

* Glucose (50 -100 mg / dl)
* Protein (7.5 - 15 mg / dl)
* pH (5-9)
* Leukocytes (9-15 leu / ul)
* Nitrite (0.05-0.1 mg/ dl)
* Urobilinogen (0.2-1.0 mg / dl)
* Blood (5-10 Ery/ul)
* Ketones (2.5-5 mg/dl)
* Bilirubin (0.4-1.0 mg/ dl)
* Specific Gravity (SG) (1,000-1,030) Test the urine parameters above using Urinalysis 10U Reagent Strips Verify (REF U031-102 exp. 2022-03-05). Pulse rate and blood pressure are measured on each visit after a 5-minute break using intelliVue MP70 (Philips, Netherlands). Personal reports are also recorded at these times. We kept the subjects maintaining their usual diet and activity, and all participants completed diet records on each visit to the clinic during the intervention period to evaluate their energy intake and diet quality. Food intake data were analyzed by a nutritionist (Melvin Junior Tanner, S.Gz).

Statistical Analysis Statistical analysis is performed using SPSS software, version 26 (IBM Corporation). Fixed effects include treatment groups, treatment visits, and interactions between treatment and visit groups. The value p\<0.05 is considered statistically significant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Aging Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The study was a 4-week, randomized, double-blind, placebo-controlled clinical trial. Evaluation during the initial visit includes physical examination in the form of Body Mass Index based on Asia-Pacific guidelines and blood parameter screening tests in the form of blood glucose, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and total cholesterol, and PGC-1α were performed on all participants within 1 week of the initial screening. A random number between 1 and 70 was generated for each subject and registered participants were scheduled for their first visit and randomly assigned to the sea grape extract group (n=35) or placebo (n=35). Sea grape extract/placebo tablets/capsules were given to participants every 1 week (1 day of consumption per oral) 15 Minutes before eating (According to the diabetes drug guidline consumtion).

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

placebo A

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo B

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo C

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo D

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo E

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo F

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo G

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo H

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo I

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo J

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo K

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo L

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo M

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo N

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo O

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo P

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo Q

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo R

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo S

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

placebo T

placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo lactose powder (1.68 g/70kg BW day-1).

sea grape extract A

given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms

Group Type EXPERIMENTAL